Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants.

Sonneveld MJ, Rijckborst V, Zwang L, Zeuzem S, Jenny Heathcote E, Simon K, Zoutendijk R, Akarca US, Pas SD, Hansen BE, Janssen HL.

Antiviral Res. 2013 Mar;97(3):312-7. doi: 10.1016/j.antiviral.2012.12.023. Epub 2012 Dec 26.

PMID:
23274785
2.

Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.

Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, Pas SD, Hansen BE, Janssen HL.

Hepatology. 2012 Jul;56(1):67-75. doi: 10.1002/hep.25636. Epub 2012 Apr 25.

PMID:
22307831
3.

Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response.

Sonneveld MJ, Zoutendijk R, Flink HJ, Zwang L, Hansen BE, Janssen HL.

Clin Infect Dis. 2013 Jan;56(1):100-5. doi: 10.1093/cid/cis859. Epub 2012 Oct 5.

4.

Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.

Sonneveld MJ, Arends P, Boonstra A, Hansen BE, Janssen HL.

J Hepatol. 2013 May;58(5):898-903. doi: 10.1016/j.jhep.2013.01.029. Epub 2013 Jan 29.

PMID:
23376362
5.

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.

Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.

Antivir Ther. 2012;17(1):9-17. doi: 10.3851/IMP1887.

PMID:
22267464
6.

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.

Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2011;16(5):629-37. doi: 10.3851/IMP1841.

PMID:
21817184
7.

Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.

Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL.

Gastroenterology. 2012 Mar;142(3):513-520.e1. doi: 10.1053/j.gastro.2011.11.025. Epub 2011 Nov 19.

PMID:
22108195
8.

Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.

Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y.

J Clin Virol. 2009 Oct;46(2):117-23. doi: 10.1016/j.jcv.2009.07.005. Epub 2009 Aug 3.

PMID:
19651540
9.

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.

Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL.

Hepatology. 2010 Oct;52(4):1251-7. doi: 10.1002/hep.23844.

PMID:
20830787
10.

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, Nosotti L, Mari T, De Santis A, Ponti ML, Sorbello O, Iacomi F, Angelico M.

Antivir Ther. 2009;14(8):1165-74. doi: 10.3851/IMP1466.

PMID:
20032546
11.

[Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].

Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY.

Zhonghua Gan Zang Bing Za Zhi. 2013 May;21(5):335-9. doi: 10.3760/cma.j.issn.1007-3418.2013.05.006. Chinese.

PMID:
24025132
12.

Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus.

Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA.

J Gastroenterol Hepatol. 2003 Jun;18(6):630-7.

PMID:
12753143
13.

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.

Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL.

Gastroenterology. 2008 Aug;135(2):459-67. doi: 10.1053/j.gastro.2008.05.031. Epub 2008 May 15.

PMID:
18585385
14.

Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.

Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, Beld M, Reesink H.

J Gastroenterol Hepatol. 2011 Oct;26(10):1527-35. doi: 10.1111/j.1440-1746.2011.06766.x.

PMID:
21557773
15.

Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.

Yang HC, Chen CL, Shen YC, Peng CY, Liu CJ, Tseng TC, Su TH, Chuang WL, Yu ML, Dai CY, Liu CH, Chen PJ, Chen DS, Kao JH.

Hepatology. 2013 Mar;57(3):934-43. doi: 10.1002/hep.26121. Epub 2013 Feb 7.

PMID:
23112104
16.

A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.

Piccolo P, Lenci I, di Paolo D, Demelia L, Sorbello O, Nosotti L, Angelico M.

Antivir Ther. 2013;18(1):57-64. doi: 10.3851/IMP2281. Epub 2012 Aug 7.

PMID:
22872648
17.

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.

Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL.

Hepatology. 2013 Sep;58(3):872-80. doi: 10.1002/hep.26436. Epub 2013 Jul 29.

PMID:
23553752
18.

Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues.

Zoutendijk R, Sonneveld MJ, Reijnders JG, van Vuuren AJ, Biesta P, Hansen BE, Boonstra A, Janssen HL.

J Viral Hepat. 2013 May;20(5):322-7. doi: 10.1111/jvh.12033. Epub 2012 Dec 5.

PMID:
23565614
20.

Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders.

Rijckborst V, Ferenci P, Akdogan M, Pinarbasi B, ter Borg MJ, Simon K, Flisiak R, Akarca US, Raptopoulou-Gigi M, Verhey E, van Vuuren AJ, Boucher CA, Hansen BE, Janssen HL; PARC Study Group.

Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1012-9.

PMID:
22668876
Items per page

Supplemental Content

Write to the Help Desk